<DOC>
	<DOCNO>NCT01500798</DOCNO>
	<brief_summary>This 24-week multi-center , double-blind , randomize , exploratory study bardoxolone methyl treatment 18 patient Stage 3 CKD ( eGFR great equal 30.0 less 60.0 ml/min/1.73m2 ) diabetes ensure least 15 patient complete study evaluation primary endpoint .</brief_summary>
	<brief_title>A Pharmacodynamic Study Measured Glomerular Filtration Rate Patients With Chronic Kidney Disease Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Screening eGFR ≥ 30.0 &lt; 60.0 mL/min/1.73 m2 ; A history type 2 diabetes ; diagnosis make ≥ 30 year age ( diabetes develop young age , fast Cpeptide level must ≥ 0.1 ng/mL confirm type 2 diabetes ) ; Male female patient least 18 year age ; Treatment angiotensin convert enzyme ( ACE ) inhibitor and/or angiotensin II receptor blocker ( ARB ) least 6 week prior Screening Visit screening . The dosage ACE inhibitor and/or ARB must stable 2 week prior Screening Visit A screening ( i.e. , change dosage medication ) . Patients take ACE inhibitor and/or ARB , take ACE inhibitor and/or ARB level goal dose set K/DOQI guideline ( See Appendix 3 ) document medical contraindication ( e.g. , hyperkalemia , dry cough , angioedema ) , investigator must discuss appropriate medical monitor ; Albumin/creatinine ratio ( ACR ) &lt; 300 mg/g ; Mean systolic blood pressure ( SBP ) must ≤ 160 mmHg ≥ 105 mmHg mean diastolic blood pressure ( DBP ) must &lt; 90 mmHg screening ; mean SBP mean DBP ( determine average three reading ) must within described range ; Willing practice method birth control ( male partner childbearing potential female childbearing potential , [ see Section 9.7 ] ) screening , take study drug least 30 day last dose study drug ingest ; Willing able cooperate aspect protocol ; Willing able give write informed consent study participation provide consent access medical data accord appropriate local data protection legislation , allow authorization access medical record describe event capture endpoint . Type 1 diabetes mellitus ( juvenile onset ) . If history diabetic ketoacidosis exists , Cpeptide level must confirm type 2 diabetes ; Known nondiabetic renal disease ( e.g. , know polycystic kidney disease family history hereditary form kidney disease ) [ nephrosclerosis superimpose diabetic kidney disease acceptable ] ; Ongoing clinical investigation evidence ( e.g. , unexplained hematuria red blood cell white blood cell cast ) suggest nondiabetic renal disease nephrosclerosis ; History renal donation , transplant plan transplant living donor study ; Hemoglobin A1c level &gt; 9.0 % ( 75 mmol/mol ) screening ; Acute dialysis acute kidney injury within 12 week prior screen screen ; Clinical sign and/or symptom uremia expect need renal replacement therapy within 12 week follow randomization , assessed investigator ; Recently active cardiovascular disease define : Unstable angina pectoris within 12 week study randomization ; Myocardial infarction , coronary artery bypass graft surgery , percutaneous transluminal coronary angioplasty/stent within 12 week study randomization ; Cerebrovascular accident , include transient ischemic attack within 12 week study randomization ; Current diagnosis Class III IV NYHA congestive heart failure ( Appendix 4 ) ; Clinical diagnosis severe obstructive valvular heart disease severe obstructive hypertrophic cardiomyopathy ; Atrioventricular block , 2o 3o , successfully treat pacemaker ; Diagnostic interventional procedure require contrast agent within 30 day prior baseline mGFR visit 1 plan study ; Systemic immunosuppression 2 week , cumulatively , within 12 week prior randomization anticipate need immunosuppression study ; Total bilirubin , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) level great upper limit normal ( ULN ) alkaline phosphatase level great two time ULN ANY screen laboratory test result ; Female patient pregnant , intend become pregnant study , nursing ; BMI &lt; 18.5 kg/m2 ; Known hypersensitivity component study drug ; Current history drug alcohol abuse , assess investigator ; Clinically significant infection require intravenous administration antibiotic hospitalization within 6 week prior Screening Visit screening ; Diagnosis treatment malignancy past 5 year , exclude nonmelanoma skin cancer carcinoma situ cervix ; A clinical condition , judgment investigator , could potentially pose health risk patient involve study ; Unable communicate cooperate investigator due language problem , poor mental development , impaired cerebral function ; Participation clinical study involve intervention within 30 day prior randomization , concurrent participation study , participation prior clinical study involve bardoxolone methyl form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>